Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Small biopharma and contract research organizations are increasingly adopting eClinical technology to keep up with regulatory and market demands for research innovation. They are paying attention to how these tools can help throughout the study lifecycle. The survey report explores 11 types of clinical trial technology and when they are used, as well as the challenges to tech adoption and how vendors can assist. The report also discusses optimism for the future and emphasizes the importance of data reliability.The Southern Blood Center is recovering from a ransomware attack, causing them to implement manual processing methods for blood. The 5th Circuit Court handed providers a legal victory in the no surprises litigation, vacating instructions that advantaged insurers. Tenet is selling a majority stake in five Alabama hospitals for $910 million to pay down debt and focus on ambulatory surgery centers. Healthcare industry trends include the use of virtual reality, robotics, and AI to improve patient engagement and clinical decision-making. Healthcare data breaches are on the rise, with an Arkansas-based provider exposing the information of over 375,000 people.Biotech entrepreneur Arie Belldegrun has launched a new 'science-first' credit firm called Symbiotic Capital with $600 million in committed capital. Roche has licensed Sangamo's technology for another shot at developing an Alzheimer's drug by repressing the gene that produces the protein tau. Biomarin is reducing spending on its hemophilia gene therapy, Roctavian, and focusing sales in the U.S., Italy, and Germany. Biotech startup Red Queen has received $55 million in funding to develop versatile antivirals, including a COVID treatment.Sangamo Therapeutics has secured an exclusive licensing agreement with Genentech, a subsidiary of Roche, to develop novel genomic medicines for neurodegenerative diseases. Genentech will pay Sangamo $50 million in upfront fees and milestone payments as part of the potential $1.9 billion deal. In other news, Biomarin Pharmaceuticals is narrowing the focus of its hemophilia A gene therapy, Roctavian, to the U.S., Germany, and Italy in an effort to reduce costs and increase profitability by 2025.Pharma giants Pfizer, GSK, and Moderna are gearing up for the respiratory syncytial virus (RSV) season, which typically starts in the fall and peaks in the winter. RSV can be dangerous for infants and older individuals, leading to hospitalization and death. The FDA has approved three vaccines for RSV, but vaccination rates among adults over 60 are low.This week in biotech news, Jim Wilson, a prominent gene therapy researcher, is leaving UPenn to start two new spinouts. Otsuka has acquired startup Jnana in an $800 million deal, adding to the recent uptick in private biotech M&A. Biotech startup Airna has raised $60 million for RNA editing medicines, while 23andMe's board has rejected CEO Wojcicki's take-private proposal. Additionally, Biotech Red Queen has launched with $55 million to develop versatile antivirals.Stay informed with Biopharma Dive for all your biotech and pharma news needs!